We are ProQR, a company on a mission to create new medicines for patients in need. We focus on a group of diseases called rare diseases, with a very high need for new medicines. Out of the approximately 7,000 rare diseases, less than 400 have a treatment, and we intend to change that. To treat these diseases we use RNA therapies, a technology that allows us to address inherited diseases that are caused by a genetic defect. Our focus is on diseases that are very severe or life threatening, and have limited treatment options. Amongst others we work on the development of new medicines for several forms of inherited blindness such as Leberâs congenital amaurosis, Usher syndrome type 2 and autosomal dominant retinitis pigmentosa. Source
No articles found.
Elevate is the first of its kind, a line of high-performance nutritional supplemen...
Elevate is the first of its kind, a line of hig...
HealthStream (NASDAQ: HSTM) is dedicated to improving patient outcomes through the...
HealthStream (NASDAQ: HSTM) is dedicated to imp...
The objective of Phenomix Sciences, LLC (Phenomix) is to provide healthcare soluti...
The objective of Phenomix Sciences, LLC (Phenom...
VistaGen Therapeutics (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company...
VistaGen Therapeutics (NASDAQ: VTGN) is a clini...
Spring Bank is a clinical-stage biopharmaceutical company engaged in the discovery...
Spring Bank is a clinical-stage biopharmaceutic...
Inovio is bringing IMMUNO-INGENUITY⢠to life and is reshaping the future of trea...
Inovio is bringing IMMUNO-INGENUITY⢠to life ...
Novelion Therapeutics Inc. (âNovelion"), headquartered in Vancouver, British Col...
Novelion Therapeutics Inc. (âNovelion"), head...
Join the National Investor Network and get the latest information with your interests in mind.